



Round Table Report 13 January 2021

For restricted use

This report summarizes the ECDC daily roundtable discussion and provides update on threats detected and monitored by Epidemic Intelligence.

Active threat

COVID-19 associated with SARS-CoV-2 - multi-country (world) - 2021

Other news:

EMA has received an application for conditional marketing authorisation for a COVID-19 vaccine developed by AstraZeneca and Oxford University. An opinion on the marketing authorisation could be issued by 29 January.

Other news

Lyssavirus infection – France – 2019 Source: media, Santé Publique France

Summary: France reported a human case of lyssavirus infection with the European Bat Lyssavirus type 1 (EBLV-1). The case was a man in his fifties who died in August 2019 from an encephalitis of unknown etiology. Post-mortem metagenomics analysis as part of a research study identified EBLV-1 infection.

A bat colony was living in the house; the case had likely been in contact with the bats although no report of scratches or bites were reported.

Background: Two human cases of EBLV-1 infection were <u>reported</u> so far, in Ukraine (1977) and Russia (1985). This is therefore the first case of human EBLV-1 infection reported in France despite EBLV-1 having previously been isolated in <u>bats</u> and in <u>cats</u> in France.

Assessment: The bats were no longer living in the house, hence it is not possible to investigate further the colony. Bat lyssaviruses represent a potential emerging threat in the EU/EEA. As a general precaution, it is recommended to avoid handling bats and their excreta and seek medical attention in case of accidental exposure (i.e. bite or scratch).

ECDC recently published a <u>summary review</u> in Eurosurveillance on the risk related to rabies, including EBLV-1 and 2 and the other divergent lyssaviruses.

Action: No action taken.

European Centre for Disease Prevention and Control (ECDC) Postal address: ECDC 169 73 Solna, Sweden Visiting address: Gustav III:s Boulevard 40, Solna, Sweden ecdc.europa.eu

Epidemic Intelligence duty email: support@ecdc.europa.eu

1/2

Risk assessment under production

Joint ECDC and EFSA rapid outbreak assessment to be produced on Salmonella Enteritidis contamination in poultry products from Poland to be published in week 03-2021.

Rapid Risk Assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update, to be circulated on 20 January 2021.

The Round Table Report contains information that could be considered sensitive or is still under verification. Its distribution is restricted to

Participants

Senior Management: -EI and Response Head of Section: -

Duty Officers:

24/7: -Threat Detection: -Rapid Assessment and Outbreaks: -Communication: -

Representative of:

Epidemic Intelligence: -Response: -Vaccine Preventable Diseases: -Emerging and Vector-borne Diseases: -Food and Water-borne Diseases: -Influenza: -Microbiology Coordination: -

European Centre for Disease Prevention and Control (ECDC) Postal address: ECDC 169 73 Solna, Sweden Visiting address: Gustav III:s Boulevard 40, Solna, Sweden ecdc.europa.eu

Epidemic Intelligence duty email: support@ecdc.europa.eu

2/2